Treatment of chronic inflammatory rheumatism by biotherapy in Gabon : eligibility and follow-up of the first 8 patients in sub-Saharan Africa

Missounga, L.; Ba, J. Iba; Ondo, Ingrid Rosalie Nseng Nseng; Madjinou, M.I.C. Nziengui; Malekou, D. Mwenpindi; Mouloungui, E.G. Mouendou; Boguikouma, J. B.

doi:10.1684/mst.2018.0781

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The frequent prescription of methotrexate could be explained on the one hand by the affordable cost and the availability of the drug in our areas and on the other hand by the high frequency of RA, methotrexate being the first-line background treatment in the management of RA according to the 2018 recommendations of the French Society of Rheumatology [32]. No patient has been treated with biotherapy, although the efficacy of biological DMARDs has been demonstrated in developed and developing countries [33]. Difficulties in its access, high cost and major side effects including high risk of infection could explain this.…”

Section: Discussionmentioning

confidence: 99%

Chronic Inflammatory Rheumatic Diseases in Rheumatological Practice in Lomé (Togo)

Kakpovi¹,

Oniankitan²,

Tagbor³

et al. 2022

OJRA

View full text Add to dashboard Cite

Chronic inflammatory rheumatism is a pathology of variable frequency and severity with a significant impact on the socio-economic, personal and family level. Study Aim: To describe the epidemiological, clinical, laboratory, radiological, therapeutic and evolutive features of chronic inflammatory rheumatic diseases in rheumatological practice in Togo. Patients and Methods: This was a multicenter cross-sectional study conducted from January 2011 to December 2019 on patients examined in the three rheumatology departments in Lomé (Togo). Patients 18 years old and above who have presented joint pain with or without synovitis, and/or rachialgia (back pain) for at least three months were included. The diagnosis of chronic inflammatory rheumatic diseases was made according to international consensus criteria. Results: Out of the 20333 patients whose files were collected during our study period, 290 (1.43%) suffered from chronic inflammatory rheumatic diseases. There were 226 (77.93%) females and 64 (22.07%) males. The mean age of the patients was 42.79 ± 15.18 years. The mean duration of symptoms was 40.80 ± 54.09 months. Arthritis (67.24%) was the main reason for consultation, followed by joint pain (31.38%). rheumatoid arthritis (41.03%), unclassified chronic inflammatory rheumatic diseases (38.62%), spondyloarthropathies (15.17%) and systemic lupus erythematosus (2.41%) were the major clinical forms. The immunological tests performed in 13.79% of cases were positive in 52.94% of cases. Carpitis (57.55%) and diffuse osteoporosis (45.28%) were the commonest radio-How to cite this paper: Kakpovi, K.,

show abstract

Section: Discussionmentioning

confidence: 99%

Chronic Inflammatory Rheumatic Diseases in Rheumatological Practice in Lomé (Togo)

Kakpovi¹,

Oniankitan²,

Tagbor³

et al. 2022

OJRA

View full text Add to dashboard Cite

show abstract

“…Le méthotrexate étant le traitement de fond de première intention dans la prise en charge de la PR selon les recommandations 2018 de la société française de rhumatologie [32]. Aucun patient n'a bénéficié d'un traitement par biothérapie, bien que l'efficacité des biothérapies sur les DMARDs a été prouvée dans les pays développés et sous-développés [33] . L'accès difficile, le coût élevé et les effets secondaires majeurs notamment le risque infectieux élevé expliqueraient cela.…”

Section: Discussionunclassified

Rhumatismes inflammatoires chroniques en consultation rhumatologique à Lomé (Togo)

Kakpovi,

Oniankitan,

Tagbor

et al. 2022

Rhum Afr Franc

View full text Add to dashboard Cite

Objectifs : décrire les aspects épidémiologiques, cliniques, paracliniques, thérapeutiques et évolutifs des rhumatismes inflammatoires chroniques en milieu rhumatologique au Togo.Matériels et méthodes: il s’est agi d’une étude multicentrique transversale menée de Janvier 2011 à Décembre 2019 sur les dossiers des patients vus dans les trois services de Rhumatologie de Lomé (Togo). A été inclus tout patient âgé d’au moins 18 ans ayant présenté depuis au moins trois mois des arthralgies avec ou sans synovite et/ou des rachialgies. Le diagnostic de rhumatisme inflammatoire chronique était retenu selon les critères de consensus internationaux.Résultats: sur les 20333 dossiers colligés pendant notre période d’étude, 290 patients souffraient de rhumatismes inflammatoires chroniques soit une fréquence hospitalière de 1,43%. Ils se répartissaient en 226 femmes (77,93%) et 64 hommes (22,07%). Leur âge moyen à la consultation était de 42,79 ± 15,18 ans. La durée moyenne d’évolutionavant la consultation était de 40,80 ± 54,09 mois. Les arthrites (56,21%) constituaient le premier motif de consultation, suivies des arthralgies (25,86%). La polyarthrite rhumatoïde (41,03%), les rhumatismes chroniques inflammatoires inclassés (38,62%), les spondyloarthrites (15,17%) et le lupus érythémateux disséminé (2,41%) étaient les principales formes cliniques. Le bilan immunologique réalisé dans 13,79% des cas était positif dans 52,94% des cas. La carpite (57,55%) et la déminéralisation osseuse (45,28%) étaient les principales lésions radiographiques. Deux cent quatrevingt-neuf patients (99,66%) ont bénéficié d’un traitement symptomatique fait essentiellement d’anti-inflammatoires non stéroïdiens (73,36%) et de corticoïdes (51,90%) et 90 patients (31,03%) d’un traitement de fond dont le méthotrexate (88,89%) comme molécule principale. L’évolution était favorable dans 27,93% des cas.Conclusion: les rhumatismes inflammatoires chroniques sont des affections courantes en milieu rhumatologique au Togo qui méritent une attention particulière. La mise en place d’un laboratoire spécialisé d’immunologie pourrait être très utile au diagnostic et à la prise en charge précoce de ces affections.

show abstract

“…The specificity of ACPA increases in the years just before the onset of RA and is higher in patients who have smoked compared to patients who have never smoked [5]. Biotherapies targeting these cytokines in the treatment of RA are rarely used in sub-Saharan Africa [6] where RA is often diagnosed in the erosive and deforming phase. In the era of biotherapies and the arrival of biosimilars in sub-Saharan Africa, the objective of this study was to describe plasma variations in Il-6 in RA patients at Cité Verte District Hospital (Cameroon).…”

Section: Introductionmentioning

confidence: 99%

Interleukin 6 and Bone Erosions in Rheumatoid Arthritis in an African Hospital

Eloundou,

Kamissoko,

Kempta

et al. 2024

OJRA

View full text Add to dashboard Cite

Introduction: Rheumatoid arthritis (RA) is a chronic, erosive and deforming inflammatory rheumatic disease. In the era of biotherapies and the arrival of biosimilars in sub-Saharan Africa, the objective of this study was to describe plasma IL-6 variations in RA patients at Cité Verte District Hospital (Cameroon). Material and Methods: Descriptive and analytical cross-sectional study from December 1, 2021 to May 31, 2022. We included patients over 18 years old suffering from RA (ACR/EULAR 2010). Patients with an infection were not included. The data collected were age, sex, smoking status, family history, disease duration, disease activity by DAS28, CRP, rheumatoid factor, and plasma level of IL-6. Bone erosion was sought on radiography and ultrasound. Result: We included 31 patients, 25 of whom were women (80.6%). The mean age was 47.27 ± 17.97 years. Disease activity was predominantly moderate (32.3%) and severe (32.3%). Mean IL-6 level was 15.29 ± 2.36 pg/ml (extremes: 11.26 pg/ml and 20.15 pg/ml). IL-6 levels were higher in patients with a history of smoking. Similarly, IL-6 levels were higher in patients with mildly active RA in remission than in moderately and severely active RA. Mean IL-6 levels were significantly higher in patients with erosive RA (16.3 pg/ml VS 14.6 pg/ml). Conclusion: IL-6 levels were significantly elevated in men, weaned smokers and patients with bone erosions.

show abstract

Treatment of chronic inflammatory rheumatism by biotherapy in Gabon : eligibility and follow-up of the first 8 patients in sub-Saharan Africa

Cited by 6 publications

References 0 publications

Chronic Inflammatory Rheumatic Diseases in Rheumatological Practice in Lomé (Togo)

Chronic Inflammatory Rheumatic Diseases in Rheumatological Practice in Lomé (Togo)

Rhumatismes inflammatoires chroniques en consultation rhumatologique à Lomé (Togo)

Interleukin 6 and Bone Erosions in Rheumatoid Arthritis in an African Hospital

Contact Info

Product

Resources

About

Treatment of chronic inflammatory rheumatism by biotherapy in Gabon : eligibility and follow-up of the first 8 patients in sub-Saharan Africa

Cited by 6 publications

References 0 publications

Chronic Inflammatory Rheumatic Diseases in Rheumatological Practice in Lom&#233; (Togo)

Chronic Inflammatory Rheumatic Diseases in Rheumatological Practice in Lom&#233; (Togo)

Rhumatismes inflammatoires chroniques en consultation rhumatologique à Lomé (Togo)

Interleukin 6 and Bone Erosions in Rheumatoid Arthritis in an African Hospital

Contact Info

Product

Resources

About

Chronic Inflammatory Rheumatic Diseases in Rheumatological Practice in Lomé (Togo)

Chronic Inflammatory Rheumatic Diseases in Rheumatological Practice in Lomé (Togo)